Lord, Abbett & Co
VERA icon

Lord, Abbett & Co’s Vera Therapeutics VERA Stock Holding History

Lord, Abbett & Co’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-148,530
Closed -$3.57M – 590
2025
Q1 		$3.57M Sell
148,530
-1,005,140
-87% -$32.3M 0.01% 486
2024
Q4 		$48.8M Buy
1,153,670
+727,656
+171% +$32.2M 0.15% 172
2024
Q3 		$18.8M Buy
426,014
+124,197
+41% +$4.71M 0.06% 336
2024
Q2 		$10.9M Buy
301,817
+76,236
+34% +$3.02M 0.04% 383
2024
Q1 		$9.73M Buy
+225,581
New +$8.04M 0.03% 403

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Lord, Abbett & Co's VERA Position: Q2 2025 in Review

Lord, Abbett & Co sold out of Vera Therapeutics (VERA) in Q2 2025, closing a stake of 148,530 shares — an estimated $3.57M sold.

Lord, Abbett & Co first reported a position in VERA in Q1 2024 and held it in 5 quarters. The position peaked at $48.8M in Q4 2024. 172 funds tracked by Wall St. Rank hold VERA as of Q2 2025.

  • Lord, Abbett & Co reported no remaining Vera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 148,530 Vera Therapeutics shares in Q2 2025, an estimated $3.57M.
  • Lord, Abbett & Co first reported a position in Vera Therapeutics in Q1 2024 and held it in 5 quarters.
  • Lord, Abbett & Co's Vera Therapeutics position peaked at $48.8M in Q4 2024.
  • 172 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2025.

Based on Lord, Abbett & Co's 13F filing for Q2 2025, filed 14 Aug 2025.